UY28255A1 - Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger - Google Patents

Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger

Info

Publication number
UY28255A1
UY28255A1 UY28255A UY28255A UY28255A1 UY 28255 A1 UY28255 A1 UY 28255A1 UY 28255 A UY28255 A UY 28255A UY 28255 A UY28255 A UY 28255A UY 28255 A1 UY28255 A1 UY 28255A1
Authority
UY
Uruguay
Prior art keywords
dosage forms
veger
inhibitors
treatment procedures
precursons
Prior art date
Application number
UY28255A
Other languages
English (en)
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithavala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY28255A1 publication Critical patent/UY28255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona formas de dosificación de un compuesto de fórmula 1: o sales, solvatos o precursones farmacológicos farmacéuticamente aceptables del mismo. La invención proporciona además procedimientos de tratamietnodel crecimiento celular anormal, tal como cánceres, mediante la administración de formas de dosificación a un mamífero.
UY28255A 2003-04-03 2004-04-02 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger UY28255A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
UY28255A1 true UY28255A1 (es) 2004-11-30

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28255A UY28255A1 (es) 2003-04-03 2004-04-02 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger

Country Status (16)

Country Link
US (1) US20040224988A1 (es)
EP (1) EP1613320A1 (es)
JP (1) JP2006522087A (es)
KR (1) KR20050119671A (es)
AR (1) AR043822A1 (es)
AU (1) AU2004226586B2 (es)
BR (1) BRPI0409230A (es)
CA (1) CA2520932A1 (es)
MX (1) MXPA05009303A (es)
NL (1) NL1025873C2 (es)
NO (1) NO20055143L (es)
PA (1) PA8599701A1 (es)
RU (2) RU2341263C2 (es)
TW (1) TW200423933A (es)
UY (1) UY28255A1 (es)
WO (1) WO2004087152A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
MX2007005291A (es) * 2004-11-02 2007-07-19 Pfizer Metodos para preparar compuestos de indazol.
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
FI2134702T4 (fi) 2007-04-05 2023-09-12 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
MX2014005715A (es) 2011-11-11 2014-05-28 Pfizer N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CN109072241A (zh) 2016-02-08 2018-12-21 维特里萨医疗公司 具有改善的玻璃体内半衰期的组合物及其用途
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2023166420A1 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
AU2004226586B2 (en) 2008-12-11
NO20055143L (no) 2006-01-03
CA2520932A1 (en) 2004-10-14
MXPA05009303A (es) 2005-10-05
TW200423933A (en) 2004-11-16
KR20050119671A (ko) 2005-12-21
RU2005128791A (ru) 2006-05-10
JP2006522087A (ja) 2006-09-28
EP1613320A1 (en) 2006-01-11
NL1025873A1 (nl) 2004-10-05
AU2004226586A1 (en) 2004-10-14
AR043822A1 (es) 2005-08-17
NL1025873C2 (nl) 2006-02-14
RU2341263C2 (ru) 2008-12-20
NO20055143D0 (no) 2005-11-02
WO2004087152A1 (en) 2004-10-14
RU2008122358A (ru) 2009-12-10
US20040224988A1 (en) 2004-11-11
PA8599701A1 (es) 2004-11-26
BRPI0409230A (pt) 2006-03-28

Similar Documents

Publication Publication Date Title
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
PA8680701A1 (es) Derivados de oxindol
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
ECSP056131A (es) Compuestos de carbonilo
UY29246A1 (es) Nuevos compuestos
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ECSP055867A (es) Derivados de pirrolopirimidina
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MX2021010321A (es) Compuestos macrociclicos.
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
GB0112348D0 (en) Compounds
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА